Director Michael Forer filed a Form 4 with the SEC on August 13, 2026, disclosing the acquisition of 102,202 share options in GH Research PLC (NASDAQ:GHRS) on August 11, 2026.

Key Highlights

  • Reporting person: Michael Forer, disclosed as a Director of GH Research PLC.
  • Two option grants: 2,202 share options and 100,000 share options, both acquired on August 11, 2026, with a transaction code of A (acquired).
  • Exercise price: Both grants carry an exercise price of $0.025 per share, with a price of $0 at grant.
  • Expiration date: Both option grants expire on August 11, 2033.
  • Vesting - 2,202 options: Immediately fully vested, but not exercisable until August 11, 2028, according to the filing.
  • Vesting - 100,000 options: 25% vest and become exercisable on August 11, 2027, with the remaining 75% vesting in equal monthly installments over three years thereafter.
  • Post-transaction ownership: Forer directly holds 2,202 derivative securities following the first grant and 100,000 derivative securities following the second grant, each held directly.

Michael Forer Option Grant Details at GH Research PLC

According to the Form 4 filed on August 13, 2026, Michael Forer, a Director of GH Research PLC, reported the acquisition of two separate tranches of Share Options (Right to Buy) in the company's ordinary shares. Both transactions were dated August 11, 2026, and carried a transaction code of A, indicating acquisition. The underlying security for both grants is ordinary shares of GH Research PLC, listed on NASDAQ:GHRS.

The first tranche consists of 2,202 share options with an exercise price of $0.025, acquired at a price of $0. Per the filing's explanation of responses, these options "are immediately fully vested, but are not exercisable until August 11, 2028." Following this transaction, Forer directly holds 2,202 derivative securities from this grant. The second tranche consists of 100,000 share options, also at an exercise price of $0.025 and acquired at a price of $0. The filing states these options "vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter." Following this transaction, Forer directly holds 100,000 derivative securities from this grant.

Both tranches carry an expiration date of August 11, 2033. The filing was signed by Michael Forer on August 13, 2026. No non-derivative securities transactions were reported in Table I of the form.

What Was Disclosed

GH Research PLC Director Michael Forer disclosed the acquisition of two tranches of share options totaling 102,202 units, both dated August 11, 2026, with an exercise price of $0.025 and expiration on August 11, 2033, with differing vesting schedules.